BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...Foundation also participated. TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2IL-17A - Interleukin-17AIL-17F - Interleukin-17FTLR8...
BioCentury | Sep 18, 2020
Product Development

Genentech finds right endpoint to show IL-6 benefit in COVID-19

...patients who require mechanical ventilation and the number of ventilator-free days are secondary endpoints. TARGETSIL-6 – Interleukin-6 Stephen...
...MRA (Informal), Actemra (Informal) Kevzara (Brand), SAR153191 (Compound #), REGN88 (Compound #), sarilumab (Generic) Genentech Inc. Regeneron Pharmaceuticals Inc. Interleukin-6...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...millionInvestors: Canaan Partners, Samsara BioCapital and The Column Group, other undisclosed investorsCEO: Debanjan RayPatents: UndisclosedTARGETSIL-2 – interleukin...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

...NIAID was the best path forward (see “Why Lilly Chose NIH’s COVID-19 Master Protocol”).TARGETSIL-6 – Interleukin-6JAK-1...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...data sharing in drug development. TARGETSIL-17 – Interleukin-17PD-1...
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

...CSF2) – Granulocyte macrophage colony-stimulating factorIL-6 – Interleukin-6SARS-CoV-2...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...ɣ chain IL-12 – Interleukin-12IL-18 – Interleukin-18 IL-18BP – Interleukin-18...
BioCentury | Aug 27, 2020
Distillery Therapeutics

IL-25 to mitigate GvHD in the GI tract after transplant

...disease scores and plasma levels of the pro-inflammatory cytokines IFNγ and IL-6, and improved survival.TARGET/MARKER/PATHWAY: Interleukin-25...
...Daigo Hashimoto, Hokkaido University, Sapporo, Japanemail: d5hash@pop.med.hokudai.ac.jpCONTACT: Takanori Teshima, same affiliation as aboveemail: teshima@med.hokudai.ac.jp Claire Quang Hokkaido University Interleukin-25...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...extrahepatic tissues (see “AstraZeneca, Silence Partner”).TARGETSEGFR (ErbB1; HER1) - Epidermal growth factor receptorIL-4R (IL-4RA; CD124) – Interleukin-4...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...Epidermal growth factor receptor 2IRAK4 – Interleukin-1...
Items per page:
1 - 10 of 2950